
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. is positioned favorably due to its focus on developing proprietary medicines addressing significant unmet medical needs in oncology, particularly with its lead drug, Endoxifen, targeting breast cancer and related conditions. The company's ongoing development of COVID-19 therapies, including inhaled and nasal spray formulations, broadens its market potential and enhances its valuation metrics. Anticipated clinical milestones are expected to serve as strong catalysts for the stock, contributing to a generally positive outlook for investors.
Bears say
Atossa Therapeutics Inc. has reported consistent net losses, amounting to $8.7 million and $8.4 million, accompanied by a recurring earnings per share (EPS) of $(0.07), which fell short of both internal and consensus estimates. The company's financial outlook is hindered by multifaceted risks, including significant balance sheet and liquidity challenges, as well as potential failures in clinical trials to prove the safety and efficacy of its product candidates. Additional concerns involve difficulties in gaining regulatory approvals, securing suitable reimbursement, and facing intense market competition, all of which contribute to a negative sentiment regarding the company's future performance.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares